The medicolegal challenges of peripheral arterial disease treatment options

As the presence of atherosclerotic peripheral arterial disease (PAD) is a marker for wider cardiovascular disease, management of the condition is not only targeted at limb-related symptoms but also includes modification of cardiovascular risk. Smoking cessation, lipid-lowering therapy, appropriate management of hypertension and diabetes, and weight management are all important components of treatment. In addition, structured exercise is a core component of treatment for patients with chronic symptomatic PAD and intermittent claudication. The benefits include improvements in walking performance, functional status and quality of life. 

Antiplatelet and lipid-lowering therapies are also important components of secondary cardiovascular prevention. Both should be tailored to the patient’s individual cardiovascular risk.   In selected patients, additional antithrombotic strategies may be appropriate, although any potential reduction in cardiovascular and limb events must be balanced against the risk of bleeding.  

Revascularisation may be considered where intermittent claudication remains significantly lifestyle-limiting despite appropriate medical treatment and structured exercise and is usually required more urgently in patients with chronic limb-threatening ischaemia (CLTI) or acute limb ischaemia (ALI). Treatment options include endovascular procedures, such as angioplasty and stenting, and open surgical reconstruction, including endarterectomy and bypass surgery. In ALI, catheter-directed thrombolysis, surgical or percutaneous thrombectomy and other endovascular techniques may also be appropriate.  

Contemporary evidence supports a patient-specific approach rather than the routine preference of one revascularisation strategy over another. Therefore, the choice of intervention should be individualised, taking into account the patient’s anatomy, complexity of the disease, severity of ischaemia, comorbidities, operative risk and importantly, the patient’s informed preferences. 

Although these procedures can be limb-saving and, in some circumstances, life-saving, they carry recognised risks arising from the underlying vascular disease, the technical aspects of the procedure and the patient’s comorbidities. Bleeding is an important complication of vascular intervention and may occur intra-operatively or postoperatively. The risk may be increased by extensive arterial calcification or atherosclerosis, previous surgery, difficult operative exposure, injury to adjacent vessels, anticoagulant or antiplatelet therapy, and disorders of coagulation. Significant postoperative haemorrhage requires prompt assessment and may necessitate correction of clotting abnormalities, blood transfusion or a return to the operating theatre. Haematoma formation may itself also result in complications, including wound breakdown, compression of adjacent structures and infection. 

Thrombosis and embolisation are additional important complications because they may compromise the circulation to an already threatened limb. Thrombosis may occur within a treated artery, stent or bypass graft and may relate to a combination of technical and patient-specific factors, including problems with blood flow into or out of the reconstructed artery, anastomotic problems at the site where vessels or a graft have been surgically joined, arterial dissection or a prothrombotic state. Manipulation or clamping of atherosclerotic arteries can also dislodge atheromatous or thrombotic material, resulting in distal embolisation. Early recognition of both in-situ thrombosis and embolisation are important, as prompt investigation and re-intervention may be required to restore blood flow and prevent irreversible ischaemia or limb loss.  

The revascularisation of a severely ischaemic limb is itself also associated with significant risk. Restoration of blood flow to previously oxygen-deprived tissues can result in reperfusion injury, causing local tissue swelling and the release of toxins into the circulation. Extensive swelling within the confined muscle compartments of the limb can lead to compartment syndrome, in which rising pressure compromises the blood supply to the muscles and nerves. If not recognised and treated promptly, this may result in irreversible tissue damage. Ischaemic muscle injury may also result in the release of potassium, myoglobin and other intracellular products, producing metabolic disturbances that can lead to cardiac arrhythmias, acute kidney injury and other serious systemic complications. Careful monitoring following revascularisation is therefore particularly important where ischaemia has been severe or prolonged. 

Other recognised complications include damage to the artery such as dissection or perforation, wound complications, infection, graft or stent occlusion and nerve injury. Prosthetic vascular graft and stent infection is uncommon but potentially serious and may result in sepsis, graft/stent failure, haemorrhage, recurrent ischaemia and limb loss. The peripheral nerves, which invariably lie close to arteries, may be injured through direct trauma, traction, compression or surgical exposure. The consequences range from temporary sensory disturbance to persistent pain, sensory loss or even motor dysfunction. 

More serious complications of vascular intervention include myocardial infarction, stroke, acute kidney injury, major limb amputation and death. The likelihood and significance of these complications vary according to the procedure undertaken, the severity and extent of the underlying vascular disease and the patient’s general health.  

Whilst the occurrence of a recognised complication does not, in itself, indicate negligent care, from a medicolegal perspective, consideration should be given to whether the intervention was appropriately indicated, whether material risks and reasonable alternatives were adequately discussed, whether the procedure was performed to an appropriate standard, and whether any subsequent complication was recognised and managed within an appropriate timeframe. Equally, intervention should not be delayed solely because treatment carries risk when the natural history of the underlying condition presents a greater and more immediate threat. This is particularly relevant in ALI and CLTI, where delay may reduce the opportunity for successful revascularisation and increase the risk of major amputation. 

In conclusion, PAD is a commonly encountered condition. Timely recognition and appropriate treatment can reduce the risk of potentially serious complications. From a medicolegal perspective, particular issues may arise where there has been an alleged delay in referral or treatment, or where complications of an intervention have occurred.